Cargando…
Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
Background: The current study desired to conduct an economic analysis on ocrelizumab (OCR), a new relapsing multiple sclerosis (RMS) treatment strategy, in comparison to natalizumab (NTL), as one of the mostly-used disease-modifying therapies (DMTs) in Iran. Methods: A 31-health-state Markov model,...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Tehran University of Medical Sciences
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984785/ http://dx.doi.org/10.18502/cjn.v20i3.7691 |